Evidence map›Paper›PMID 41958467›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2026

Cannabidiol Use in Inflammatory Bowel Disease: Insights From a Gastroenterology Outpatient Population.

Karina Fatakhova, Muhammad Jahanzaib Khan, Royce Perera, Sapphire Perera, Benjamin Glazebnik, Lindsey Donnelly, Pratik Patel, Emily Glazer, Greg Haggerty, Hassam Ali and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Karina FatakhovaDivision of Gastroenterology and Hepatology Northwell, Mather Hospital and Zucker School of Medicine at Hofstra University Port Jefferson New York USA.
Muhammad Jahanzaib KhanDivision of Gastroenterology and Hepatology Northwell, Mather Hospital and Zucker School of Medicine at Hofstra University Port Jefferson New York USA.
Royce PereraCornell University Ithaca New York USA.
Sapphire PereraNew York University New York New York USA.
Benjamin GlazebnikVassar College Poughkeepsie New York USA.
Lindsey DonnellyDivision of Gastroenterology and Hepatology Northwell, Mather Hospital and Zucker School of Medicine at Hofstra University Port Jefferson New York USA.
Pratik PatelDivision of Gastroenterology and Hepatology University of South Florida Tampa Florida USA.
Emily GlazerDivision of Gastroenterology and Hepatology Northwell, Mather Hospital and Zucker School of Medicine at Hofstra University Port Jefferson New York USA.
Greg HaggertyDivision of Gastroenterology and Hepatology Northwell, Mather Hospital and Zucker School of Medicine at Hofstra University Port Jefferson New York USA.
Hassam AliDivision of Gastroenterology and Hepatology East Carolina University Greenville North Carolina USA.ORCID https://orcid.org/0000-0001-5546-9197
Ramona RajapakseDivision of Gastroenterology and Hepatology Northwell, Mather Hospital and Zucker School of Medicine at Hofstra University Port Jefferson New York USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cannabidiol (CBD) is increasingly used for symptom relief in chronic conditions, yet its role in inflammatory bowel disease (IBD) remains underexplored. We surveyed 229 IBD patients and found that 10.5% used CBD, primarily for anxiety (54.2%), insomnia (41.7%), and pain (41.7%). Among users, 87.5% perceived benefit. Most users were female, and one-third were on biologics. These findings highlight the growing interest in alternative therapies and the need for further research on CBD's safety, efficacy, and clinical guidance in IBD care.

Indexed as

Cannabidiolcomplementary therapiesinflammatory bowel diseasespatient reported outcomessurveys and questionnaires

Identifiers

PMID41958467
PMCPMC13056695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.